SCHEMBL6033558

SCHEMBL6033558

FC(F)(F)c1ccc(Nc2ncnc(Cl)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.48
KCNH2 Q12809 1/20 0.48
SCN9A Q15858 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
SLC6A2 P23975 1/20 0.47
PDE4A P27815 1/20 0.47
KDR P35968 1/20 0.47
CHRNA7 P36544 1/20 0.47
SYK P43405 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TRPV1 Q8NER1 2/20 0.44
CDK2 P24941 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ATF1 P18846 1/20 0.44
NFKB1 P19838 1/20 0.44
KCNH3 Q9ULD8 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
CTSC P53634 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28037898 0.88 KCNH2 (0.54) KCNH2SCN9AADORA3SLC6A2PDE4A
SCHEMBL28051330 0.87 ADORA3 (0.59) APPKCNH2SCN9AADORA3SLC6A2
SCHEMBL5466853 0.83 APP (0.60) APPCHRNA7KDM4ESMN1; SMN2NFKB1
SCHEMBL27589799 0.81 SMN1; SMN2 (0.65) APPKCNH2SCN9AADORA3SLC6A2
SCHEMBL2352230 0.81 ADORA3 (0.69) KCNH2SCN9AADORA3SLC6A2PDE4A
SCHEMBL28051498 0.81 IDH2 (0.53) KCNH2SCN9ASYKKDM4ECDK2
SCHEMBL13064959 0.81 KDM4E (0.69) KCNH2SCN9AADORA3SLC6A2PDE4A
SCHEMBL28051328 0.80 TRPV1 (0.58) KDM4ETRPV1CDK2SMN1; SMN2KCNH3
SCHEMBL28051435 0.80 KDM4E (0.56) APPSYKKDM4EKCNH3CTSC
SCHEMBL6033627 0.79 APP (0.59) APPKDRCHRNA7KDM4ECDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103254144-A Cyanuric chloride derivative, and preparation method and application thereof WUHAN INST TECHNOLOGY 2013-08-21 CN claimed
CN-102746246-A 2,4-dichloro-6-(4-aminobenzotrifluoride)-1,3,5-triazine and preparation method and application thereof WUHAN INST TECHNOLOGY 2012-10-24 CN claimed
CN-102442960-A Cyanuric chloride derivative and preparation method and application thereof WUHAN INST TECHNOLOGY 2012-05-09 CN claimed
EP-2760843-B1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2016-03-02 EP disclosed
US-8841301-B2 Selective NR2B antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-23 US disclosed
EP-2760843-A2 SELECTIVE NR2B ANTAGONISTS Bristol-Myers Squibb Company (US) 2014-08-06 EP disclosed
CN-103254144-A Cyanuric chloride derivative, and preparation method and application thereof WUHAN INST TECHNOLOGY 2013-08-21 CN disclosed
WO-2013049164-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 WO disclosed
WO-2013048949-A2 SELECTIVE NR2B ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 WO disclosed
US-20130079338-A1 Selective NR2B Antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-03-28 US disclosed
CN-102746246-A 2,4-dichloro-6-(4-aminobenzotrifluoride)-1,3,5-triazine and preparation method and application thereof WUHAN INST TECHNOLOGY 2012-10-24 CN disclosed
CN-102442960-A Cyanuric chloride derivative and preparation method and application thereof WUHAN INST TECHNOLOGY 2012-05-09 CN disclosed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079338-A1 Selective NR2B Antagonists GRIN2B, GRIN2A, GRIN3A APP 1124/4885KCNH2 923/4885SCN9A 295/4885
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 APP 4260/4885KCNH2 102/4885SCN9A 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.